S&P 500   3,975.33 (+1.90%)
DOW   31,910.97 (+2.08%)
QQQ   292.50 (+1.32%)
AAPL   142.41 (+3.50%)
MSFT   259.91 (+2.91%)
FB   194.50 (+0.50%)
GOOGL   2,225.25 (+2.16%)
AMZN   2,125.98 (-1.20%)
TSLA   668.89 (+0.75%)
NVDA   167.00 (+0.04%)
BABA   86.41 (-0.44%)
NIO   15.70 (-4.50%)
AMD   94.11 (+0.65%)
CGC   5.13 (-7.07%)
MU   69.33 (+0.62%)
T   20.88 (+2.35%)
GE   75.93 (+0.90%)
F   12.84 (+2.72%)
DIS   104.89 (+2.41%)
AMC   11.62 (-3.41%)
PFE   53.06 (+1.12%)
PYPL   80.75 (+0.26%)
NFLX   184.61 (-0.93%)
S&P 500   3,975.33 (+1.90%)
DOW   31,910.97 (+2.08%)
QQQ   292.50 (+1.32%)
AAPL   142.41 (+3.50%)
MSFT   259.91 (+2.91%)
FB   194.50 (+0.50%)
GOOGL   2,225.25 (+2.16%)
AMZN   2,125.98 (-1.20%)
TSLA   668.89 (+0.75%)
NVDA   167.00 (+0.04%)
BABA   86.41 (-0.44%)
NIO   15.70 (-4.50%)
AMD   94.11 (+0.65%)
CGC   5.13 (-7.07%)
MU   69.33 (+0.62%)
T   20.88 (+2.35%)
GE   75.93 (+0.90%)
F   12.84 (+2.72%)
DIS   104.89 (+2.41%)
AMC   11.62 (-3.41%)
PFE   53.06 (+1.12%)
PYPL   80.75 (+0.26%)
NFLX   184.61 (-0.93%)
S&P 500   3,975.33 (+1.90%)
DOW   31,910.97 (+2.08%)
QQQ   292.50 (+1.32%)
AAPL   142.41 (+3.50%)
MSFT   259.91 (+2.91%)
FB   194.50 (+0.50%)
GOOGL   2,225.25 (+2.16%)
AMZN   2,125.98 (-1.20%)
TSLA   668.89 (+0.75%)
NVDA   167.00 (+0.04%)
BABA   86.41 (-0.44%)
NIO   15.70 (-4.50%)
AMD   94.11 (+0.65%)
CGC   5.13 (-7.07%)
MU   69.33 (+0.62%)
T   20.88 (+2.35%)
GE   75.93 (+0.90%)
F   12.84 (+2.72%)
DIS   104.89 (+2.41%)
AMC   11.62 (-3.41%)
PFE   53.06 (+1.12%)
PYPL   80.75 (+0.26%)
NFLX   184.61 (-0.93%)
S&P 500   3,975.33 (+1.90%)
DOW   31,910.97 (+2.08%)
QQQ   292.50 (+1.32%)
AAPL   142.41 (+3.50%)
MSFT   259.91 (+2.91%)
FB   194.50 (+0.50%)
GOOGL   2,225.25 (+2.16%)
AMZN   2,125.98 (-1.20%)
TSLA   668.89 (+0.75%)
NVDA   167.00 (+0.04%)
BABA   86.41 (-0.44%)
NIO   15.70 (-4.50%)
AMD   94.11 (+0.65%)
CGC   5.13 (-7.07%)
MU   69.33 (+0.62%)
T   20.88 (+2.35%)
GE   75.93 (+0.90%)
F   12.84 (+2.72%)
DIS   104.89 (+2.41%)
AMC   11.62 (-3.41%)
PFE   53.06 (+1.12%)
PYPL   80.75 (+0.26%)
NFLX   184.61 (-0.93%)
NASDAQ:NTEC

Intec Pharma (NTEC) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
N/A
50-Day Range
$9.15
$36.20
52-Week Range
N/A
Volume
988,300 shs
Average Volume
543,436 shs
Market Capitalization
$8.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.83

Receive NTEC News and Ratings via Email

Sign-up to receive the latest news and ratings for Intec Pharma and its competitors with MarketBeat's FREE daily newsletter.

Intec Pharma logo

About Intec Pharma

Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvika Joseph on October 23, 2000 and is headquartered in Jerusalem, Israel.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NTEC
Fax
N/A
Employees
40
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$16.18 per share

Profitability

Net Income
$-14.13 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$8.65 million
Optionable
Optionable

Company Calendar

Last Earnings
5/17/2021
Today
5/23/2022

MarketRank

Overall MarketRank

0.85 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -













Intec Pharma (NASDAQ:NTEC) Frequently Asked Questions

How were Intec Pharma's earnings last quarter?

Intec Pharma Ltd (NASDAQ:NTEC) issued its earnings results on Monday, May, 17th. The biotechnology company reported ($3.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.48) by $0.36.
View Intec Pharma's earnings history
.

When did Intec Pharma's stock split? How did Intec Pharma's stock split work?

Shares of Intec Pharma reverse split on Tuesday, July 27th 2021. The 1-4 reverse split was announced on Tuesday, July 27th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 27th 2021. An investor that had 100 shares of Intec Pharma stock prior to the reverse split would have 25 shares after the split.

Who are Intec Pharma's key executives?
Intec Pharma's management team includes the following people:
  • Jeffrey A. Meckler, Vice Chairman & Chief Executive Officer
  • Nir Sassi, President & Chief Financial Officer
  • Michael James Newman, Director & Chief Scientific Officer
  • Anna Hotovely-Salomon, Director-Clinical Affairs
  • Walt A. Linscott, Chief Business Officer
What other stocks do shareholders of Intec Pharma own?
When did Intec Pharma IPO?

(NTEC) raised $30 million in an IPO on Tuesday, August 4th 2015. The company issued 5,000,000 shares at a price of $6.00 per share. Maxim Group and Roth Capital Partners served as the underwriters for the IPO.

What is Intec Pharma's stock symbol?

Intec Pharma trades on the NASDAQ under the ticker symbol "NTEC."

How much money does Intec Pharma make?

Intec Pharma has a market capitalization of $0.00. The biotechnology company earns $-14.13 million in net income (profit) each year or ($16.32) on an earnings per share basis.

How many employees does Intec Pharma have?

Intec Pharma employs 40 workers across the globe.

What is Intec Pharma's official website?

The official website for Intec Pharma is www.intecpharma.com.

How can I contact Intec Pharma?

Intec Pharma's mailing address is 12 HARTOM STREET HAR HOTZVIM, JERUSALEM L3, 777512. The biotechnology company can be reached via phone at (722) 586-4657 or via email at [email protected].

This page was last updated on 5/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.